Cover Image

Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV‐infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV cure programme. Authors' reply

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Author:	Chan Xie
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV‐infected individuals treated with pegylated interferon—implications for stopping rules and the HBV cure programme
by: James Lok
Published: (2024)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance. Authors' Reply
by: Terry Cheuk‐Fung Yip, et al.
Published: (2025)

Editorial: HBV Integration—A Possible Key Driver on the Course of Patients With Chronic HBV Infection Under Viral Suppression. Authors' Reply
by: Qin Ning, et al.
Published: (2025)

Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC
by: Naohiro Yasuura, et al.
Published: (2024)

Editorial: Assessing the Prognosis of Patients With HBV and ACLF—Comorbidities Matter. Authors' Reply
by: Jiong Yu, et al.
Published: (2024)

Letter: Antiviral Prophylaxis Mitigates HBV Reactivation Risk During Cancer Immunotherapy: Unresolved Challenges and Future Directions—Authors' Reply
by: Landon Long Chan, et al.
Published: (2025)

Editorial: HBV Integration: A Possible Key Driver in the Course of Patients With Chronic HBV Infection Under Viral Suppression
by: Hidenori Toyoda
Published: (2025)

Letter on “Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma”–Authors' Reply
by: Subin Heo, et al.
Published: (2025)

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis. Authors' Reply
by: Bingqiong Wang, et al.
Published: (2025)

Letter: Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma—Authors' Reply
by: Jiwon Yang, et al.
Published: (2025)

Editorial: How to Interpret Clinical Impact of Viral Replication Activity for Postoperative Recurrence of HBV‐Related HCC—Authors' Reply
by: Subin Heo, et al.
Published: (2025)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply
by: Ying‐Nan Tsai, et al.
Published: (2025)

Editorial: Beyond DNA Suppression: HBV RNA as a Predictor of Hepatocarcinogenesis
by: Toshifumi Tada
Published: (2025)

Unstable Recompensation: An Intermediate Subtype in Patients With HBV ‐Related Decompensated Cirrhosis
by: Shuai Xia, et al.
Published: (2025)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance
by: Romeo Kuo‐Cheng Wu, et al.
Published: (2025)

Editorial: How does the risk of hepatocellular carcinoma change over time in patients with a hepatitis C cure? Authors' reply
by: Philip Vutien, et al.
Published: (2024)

Editorial: Quantity is important! Authors' reply
by: Marika Rudler, et al.
Published: (2024)

Letter on ‘Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma’
by: Dong Hyun Kim, et al.
Published: (2025)

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis
by: Stephanie Tsai, et al.
Published: (2025)

Letter: Using Anti‐ HBs Titres to Tailor HBV Reactivation Monitoring in Patients With Solid Tumours
by: Tsutomu Nishida, et al.
Published: (2026)

Letter: Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma
by: Sifu Yang
Published: (2025)

Letter: Optimising Prevention of Adverse Events and Antiviral Prophylaxis for HBV ‐Infected HCC Patients Undergoing Immunotherapy
by: Jialing Wang, et al.
Published: (2025)

Editorial: How to Interpret Clinical Impact of Viral Replication Activity for Postoperative Recurrence of HBV‐Related HCC
by: Beom Kyung Kim
Published: (2025)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors
by: Stefan Mauss
Published: (2025)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
by: Kyle Staller, et al.
Published: (2024)

Editorial: Another brick in the CDST wall: Authors' reply
by: Kyuwon Kim, et al.
Published: (2024)

Editorial: A Step Back to Leap Forward—Strategic Nucleos(t)ide Analogue Discontinuation Towards HBV Functional Cure
by: Xuwen Xu, et al.
Published: (2025)

Letter: Does Serum HBV RNA Add Incremental Value for Hepatocellular Carcinoma Risk Stratification Beyond Established Predictors?
by: Yuanyan Sun, et al.
Published: (2026)

Letter on “Immigration Factors and Monitoring of Chronic Hepatitis B Infection Among Foreign‐Born: The FOCUS‐HBV Multicentre Cohort”
by: Dong Hyun Kim, et al.
Published: (2025)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
by: Carolin V. Schneider, et al.
Published: (2024)

Editorial: Recompensation in PBC is good. But is it good enough? Authors' reply
by: Benedikt Silvester Hofer, et al.
Published: (2024)

Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC
by: Xiaosong Li, et al.
Published: (2024)

Editorial: The microbiome and gastric mucosal protection in aspirin users—Authors' reply
by: Nina Løn, et al.
Published: (2024)

Letter: The enigma of angiotensin receptor blocker‐associated enteropathy—Authors' reply
by: Annalisa Schiepatti, et al.
Published: (2024)

Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply
by: Matthias Lenfant, et al.
Published: (2024)

Editorial: Can we predict or not predict response to hypnotherapy? That is the question. Authors' reply
by: Dipesh H. Vasant, et al.
Published: (2024)

Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply
by: Abhinav Vasudevan, et al.
Published: (2024)

Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply
by: Matthias Lenfant, et al.
Published: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply
by: Elliot B. Tapper, et al.
Published: (2024)

Letter: Dietary emulsifiers and intestinal health—The beginning of an evolving story: Authors’ reply
by: Jessica A. Fitzpatrick, et al.
Published: (2024)